Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
7.3 EUR | -1.48% | +8.96% | +70.56% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.42M | Sales 2024 * | 37.83M 41.1M | Capitalization | 161M 175M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.99M | Net income 2024 * | -5M -5.43M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 36.62M | Net Debt 2024 * | 46.6M 50.63M | EV / Sales 2024 * | 5.48 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-17.2
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | -1.48% | ||
1 week | +8.96% | ||
Current month | +29.43% | ||
1 month | +22.28% | ||
3 months | +111.59% | ||
6 months | +57.67% | ||
Current year | +70.56% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 7.3 | -1.48% | 107 262 |
24-05-17 | 7.41 | -1.72% | 212,142 |
24-05-16 | 7.54 | +1.21% | 208,896 |
24-05-15 | 7.45 | +3.19% | 209,746 |
24-05-14 | 7.22 | +7.76% | 475,224 |
Real-time Euronext Paris, May 20, 2024 at 07:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.56% | 175M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- OSE Stock